EUVIMEDEUVIMED entdecken
Netzwerk-MetaanalyseSystematische ÜbersichtOpen Access

Antiviral Medications for Treatment of Nonsevere Influenza

Ya Gao, Yunli Zhao, Ming Liu, Shuyue Luo, Yamin Chen, Xiaoyan Chen, Qingyong Zheng, Jianguo Xu, Yanjiao Shen, Wanyu Zhao, Zhifan Li, Sha Huang und 4 weitere

JAMA Internal Medicine · 2025

DOI: 10.1001/jamainternmed.2024.7193 ↗

Kurz gefasst

Netzwerk-Metaanalyse in der Zeitschrift JAMA Internal Medicine, 2025. Verfasst von Ya Gao und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biostatistics, School of Public Health, Cheeloo College of Medicine, Shandong University, Jinan, China. Hauptthemen laut MEDLINE: Antiviral Agents, Influenza, Human. Die Arbeit wurde bisher 51-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance The optimal antiviral drug for treatment of nonsevere influenza remains unclear.

Objective

To compare effects of antiviral drugs for treating nonsevere influenza. Data Sources MEDLINE, Embase, CENTRAL, CINAHL, Global Health, Epistemonikos, and ClinicalTrials.gov were searched from database inception to September 20, 2023. Study Selection Randomized clinical trials comparing direct-acting influenza antiviral drugs to placebo, standard care, or another antiviral drug for treating people with nonsevere influenza. Data Extraction and Synthesis Paired reviewers independently performed data extraction and risk of bias assessment. A frequentist network meta-analysis was performed to summarize the evidence and the certainty of evidence was evaluated using the GRADE approach. Main Outcomes and Measures Mortality, admission to hospital, admission to the intensive care unit, duration of hospitalization, time to alleviation of symptoms, emergence of resistance, and adverse events.

Results

Overall, 73 trials with 34 332 participants proved eligible. Compared with standard care or placebo, all antiviral drugs had little or no effect on mortality for low-risk patients and high-risk patients (all high certainty). All antiviral drugs (no data for peramivir and amantadine) had little or no effect on hospital admission for low-risk patients (high certainty). For hospital admission in high-risk patients, oseltamivir (risk difference [RD], −0.4%; 95% CI, −1.0 to 0.4; high certainty) had little or no effect and baloxavir may have reduced risk (RD, −1.6%; 95% CI, −2.0 to 0.4; low certainty); all other drugs may have had little or uncertain effect. For time to alleviation of symptoms, baloxavir probably reduced symptom duration (mean difference [MD], −1.02 days; 95% CI, −1.41 to −0.63; moderate certainty); umifenovir may have reduced symptom duration (MD, −1.10 days; 95% CI, −1.57 to −0.63; low certainty); oseltamivir probably had no important effect (MD, −0.75 days; 95% CI, −0.93 to −0.57; moderate certainty). For adverse events related to treatment, baloxavir (RD, −3.2%; 95% CI, −5.2 to −0.6; high certainty) had few or no adverse events; oseltamivir (RD, 2.8%; 95% CI, 1.2 to 4.8; moderate certainty) probably increased adverse events. Conclusions and Relevance This systematic review and meta-analysis found that baloxavir probably reduced risk of hospital admission for high-risk patients and may reduce time to alleviation of symptoms, without increasing adverse events related to treatment in patients with nonsevere influenza. All other antiviral drugs either probably have little or no effect, or uncertain effects on patient-important outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsInfluenza, HumanHumansHospitalizationOseltamivirRandomized Controlled Trials as Topic

Substanzen

Antiviral AgentsOseltamivir

Autor:innen und Institutionen

  • Department of Biostatistics, School of Public Health, Cheeloo College of Medicine, Shandong University, Jinan, China.
  • Healthcare Big Data Research Institute, School of Public Health, Cheeloo College of Medicine, Shandong University, Jinan, China.
  • Evidence-Based Medicine Center, School of Basic Medical Sciences, Lanzhou University, Lanzhou, China.
  • Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada.
  • Department of Geriatric Medicine, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
  • Chongqing Municipality Clinical Research Center for Geriatrics, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.

Zitieren

APA

Gao, Y., Zhao, Y., Liu, M., Luo, S., Chen, Y., Chen, X., Zheng, Q., Xu, J., Shen, Y., Zhao, W., Li, Z., Huang, S., Huang, J., Tian, J., Guyatt, G., & Hao, Q. (2025). Antiviral Medications for Treatment of Nonsevere Influenza. JAMA Internal Medicine. https://doi.org/10.1001/jamainternmed.2024.7193

Vancouver

Gao Y, Zhao Y, Liu M, Luo S, Chen Y, Chen X, et al. Antiviral Medications for Treatment of Nonsevere Influenza. JAMA Internal Medicine. 2025. doi:10.1001/jamainternmed.2024.7193

BibTeX
@article{Gao2025,
  author = {Gao, Ya and Zhao, Yunli and Liu, Ming and Luo, Shuyue and Chen, Yamin and Chen, Xiaoyan and Zheng, Qingyong and Xu, Jianguo and Shen, Yanjiao and Zhao, Wanyu and Li, Zhifan and Huang, Sha and Huang, Jie and Tian, Jinhui and Guyatt, Gordon and Hao, Qiukui},
  title = {Antiviral Medications for Treatment of Nonsevere Influenza},
  journal = {JAMA Internal Medicine},
  year = {2025},
  doi = {10.1001/jamainternmed.2024.7193}
}
Kostenlos starten →